Aldesleukin Completed Phase 2 Trials for Multiple Myeloma and Plasma Cell Neoplasm / Chronic Myeloproliferative Disorders / Myelodysplastic Syndromes / Unspecified Adult Solid Tumor, Protocol Specific / Precancerous/Nonmalignant Condition / Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00002504Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
NCT00616720Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
NCT00274846Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00003148Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
NCT00005948Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
NCT00008190Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
NCT00059904Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
NCT00006264Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
NCT00004231Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma